Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...

If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to ...

Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ESSA Pharma between ...

Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) ...

2. Clarity Pharmaceuticals. Clarity receives U.S. FDA Fast Track Designation for 64Cu-SAR-bisPSMA in biochemical recurrence of prostate cancer. https://www.claritypharmaceuticals.com/news/ftd-2/ ...

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Pomerantz LLP announces that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or the "Company") and certain officers.  The class action, filed in the United States District Court ...

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

The primary endpoint of the trial was rPFS, defined as the time from the date of randomization to first objective evidence of radiographic progression by blinded independent central review (BICR ...

PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.

Talazoparib and enzalutamide combination significantly improved overall ... to first objective evidence of radiographic progression by blinded independent central review (BICR), or death, whichever ...